Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
6.53
+0.13 (2.03%)
Mar 9, 2026, 1:17 PM EDT - Market open
Aptevo Therapeutics Employees
Aptevo Therapeutics had 37 employees as of December 31, 2024. The number of employees decreased by 3 or -7.50% compared to the previous year.
Employees
37
Change (1Y)
-3
Growth (1Y)
-7.50%
Revenue / Employee
n/a
Profits / Employee
-$755,459
Market Cap
6.52M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 117 |
| Processa Pharmaceuticals | 10 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 9 |
| Aprea Therapeutics | 8 |
| Immuron | 7 |
| Mustang Bio | 6 |
| Can-Fite BioPharma | 5 |
APVO News
- 4 weeks ago - Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth - Accesswire
- 2 months ago - Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality - Accesswire
- 2 months ago - Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split - Accesswire
- 3 months ago - Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 - Accesswire
- 4 months ago - Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors - Accesswire
- 4 months ago - Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update - Accesswire
- 5 months ago - Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter - Accesswire
- 6 months ago - Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML - Accesswire